Advertisement

2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
  • Cynthia M. Tracy
    Search for articles by this author
  • Author Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    Andrew E. Epstein
    Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    Search for articles by this author
  • Author Footnotes
    † ACCF/AHA Representative.
    Dawood Darbar
    Footnotes
    † ACCF/AHA Representative.
    Search for articles by this author
  • Author Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    ,
    Author Footnotes
    ‡ Heart Rhythm Society Representative.
    John P. DiMarco
    Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    ‡ Heart Rhythm Society Representative.
    Search for articles by this author
  • Author Footnotes
    † ACCF/AHA Representative.
    Sandra B. Dunbar
    Footnotes
    † ACCF/AHA Representative.
    Search for articles by this author
  • Author Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    ,
    Author Footnotes
    § ACCF/AHA Task Force on Performance Measures Liaison.
    N.A. Mark Estes III
    Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    § ACCF/AHA Task Force on Performance Measures Liaison.
    Search for articles by this author
  • Author Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    ,
    Author Footnotes
    ∥ American Association for Thoracic Surgery Representative.
    ,
    Author Footnotes
    ¶ Society of Thoracic Surgeons Representative.
    T. Bruce Ferguson Jr
    Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    ∥ American Association for Thoracic Surgery Representative.
    ¶ Society of Thoracic Surgeons Representative.
    Search for articles by this author
  • Author Footnotes
    ‡ Heart Rhythm Society Representative.
    Stephen C. Hammill
    Footnotes
    ‡ Heart Rhythm Society Representative.
    Search for articles by this author
  • Author Footnotes
    † ACCF/AHA Representative.
    Pamela E. Karasik
    Footnotes
    † ACCF/AHA Representative.
    Search for articles by this author
  • Author Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    ,
    Author Footnotes
    † ACCF/AHA Representative.
    Mark S. Link
    Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    † ACCF/AHA Representative.
    Search for articles by this author
  • Author Footnotes
    † ACCF/AHA Representative.
    Joseph E. Marine
    Footnotes
    † ACCF/AHA Representative.
    Search for articles by this author
  • Author Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    ,
    Author Footnotes
    † ACCF/AHA Representative.
    Mark H. Schoenfeld
    Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    † ACCF/AHA Representative.
    Search for articles by this author
  • Author Footnotes
    ‡ Heart Rhythm Society Representative.
    Amit J. Shanker
    Footnotes
    ‡ Heart Rhythm Society Representative.
    Search for articles by this author
  • Author Footnotes
    † ACCF/AHA Representative.
    Michael J. Silka
    Footnotes
    † ACCF/AHA Representative.
    Search for articles by this author
  • Author Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    ,
    Author Footnotes
    # Heart Failure Society of America Representative.
    Lynne Warner Stevenson
    Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    # Heart Failure Society of America Representative.
    Search for articles by this author
  • Author Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    ,
    Author Footnotes
    ⁎⁎ ACCF/AHA Task Force on Practice Guidelines Liaison.
    William G. Stevenson
    Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    ⁎⁎ ACCF/AHA Task Force on Practice Guidelines Liaison.
    Search for articles by this author
  • Author Footnotes
    † ACCF/AHA Representative.
    Paul D. Varosy
    Footnotes
    † ACCF/AHA Representative.
    Search for articles by this author
  • Author Footnotes
    ⁎ Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
    † ACCF/AHA Representative.
    ‡ Heart Rhythm Society Representative.
    § ACCF/AHA Task Force on Performance Measures Liaison.
    ∥ American Association for Thoracic Surgery Representative.
    ¶ Society of Thoracic Surgeons Representative.
    # Heart Failure Society of America Representative.
    ⁎⁎ ACCF/AHA Task Force on Practice Guidelines Liaison.
Published:September 13, 2012DOI:https://doi.org/10.1016/j.hrthm.2012.08.021
      Andrew E. Epstein, MD, FACC, FAHA, FHRS, Chair; John P. DiMarco, MD, PhD, FACC, FHRS; Kenneth A. Ellenbogen, MD, FACC, FAHA, FHRS; N.A. Mark Estes III, MD, FACC, FAHA, FHRS; Roger A. Freedman, MD, FACC, FHRS; Leonard S. Gettes, MD, FACC, FAHA; A. Marc Gillinov, MD, FACC, FAHA; Gabriel Gregoratos, MD, FACC, FAHA; Stephen C. Hammill, MD, FACC, FHRS; David L. Hayes, MD, FACC, FAHA, FHRS; Mark A. Hlatky, MD, FACC, FAHA; L. Kristin Newby, MD, FACC, FAHA; Richard L. Page, MD, FACC, FAHA, FHRS; Mark H. Schoenfeld, MD, FACC, FAHA, FHRS; Michael J. Silka, MD, FACC; Lynne Warner Stevenson, MD, FACC; Michael O. Sweeney, MD, FACC

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • ACCF/AHA Task Force on Practice Guidelines
        Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines.
        (2010) (Accessed May 16, 2012)
        • Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine
        Finding What Works in Health Care: Standards for Systematic Reviews.
        The National Academies Press, Washington, DC2011
        • Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine
        Clinical Practice Guidelines We Can Trust.
        The National Academies Press, Washington, DC2011
        • Epstein A.E.
        • DiMarco J.P.
        • Ellenbogen K.A.
        • et al.
        ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices).
        J Am Coll Cardiol. 2008; 51: e1-e62
        • Gersh B.J.
        • Maron B.J.
        • Bonow R.O.
        • et al.
        2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2011; 58: e212-e260
        • Ackerman M.J.
        • Priori S.G.
        • Willems S.
        • et al.
        HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies.
        Heart Rhythm. 2011; 8: 1308-1339
        • Horner J.M.
        • Kinoshita M.
        • Webster T.L.
        • et al.
        Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience.
        Heart Rhythm. 2010; 7: 1616-1622
        • Schwartz P.J.
        • Spazzolini C.
        • Priori S.G.
        • et al.
        Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?.
        Circulation. 2010; 122: 1272-1282
        • Berul C.I.
        • Van Hare G.F.
        • Kertesz N.J.
        • et al.
        Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients.
        J Am Coll Cardiol. 2008; 51: 1685-1691
        • Barsheshet A.
        • Wang P.J.
        • Moss A.J.
        • et al.
        Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy).
        J Am Coll Cardiol. 2011; 57: 2416-2423
        • Silka M.J.
        • Bar-Cohen Y.
        Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD?.
        Circ Arrhythm Electrophysiol. 2008; 1: 298-306
        • Khairy P.
        • Harris L.
        • Landzberg M.J.
        • et al.
        Implantable cardioverter-defibrillators in tetralogy of Fallot.
        Circulation. 2008; 117: 363-370
        • van der Hulst A.E.
        • Delgado V.
        • Blom N.A.
        • et al.
        Cardiac resynchronization therapy in paediatric and congenital heart disease patients.
        Eur Heart J. 2011; 32: 2236-2246
        • Lampert R.
        • Hayes D.L.
        • Annas G.J.
        • et al.
        HRS expert consensus statement on the management of cardiovascular implantable electronic devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy.
        Heart Rhythm. 2010; 7: 1008-1026
        • Wilkoff B.L.
        • Auricchio A.
        • Brugada J.
        • et al.
        HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations.
        Heart Rhythm. 2008; 5: 907-925
        • Abraham W.T.
        • Fisher W.G.
        • Smith A.L.
        • et al.
        Cardiac resynchronization in chronic heart failure.
        N Engl J Med. 2002; 346: 1845-1853
        • Bristow M.R.
        • Saxon L.A.
        • Boehmer J.
        • et al.
        Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
        N Engl J Med. 2004; 350: 2140-2150
        • Cleland J.G.F.
        • Daubert J.-C.
        • Erdmann E.
        • et al.
        The effect of cardiac resynchronization on morbidity and mortality in heart failure.
        N Engl J Med. 2005; 352: 1539-1549
        • Hunt S.A.
        • Abraham W.T.
        • Chin M.H.
        • et al.
        2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2009; 119: e391-e479
        • Moss A.J.
        • Hall W.J.
        • Cannom D.S.
        • et al.
        Cardiac-resynchronization therapy for the prevention of heart-failure events.
        N Engl J Med. 2009; 361: 1329-1338
        • Tang A.S.L.
        • Wells G.A.
        • Talajic M.
        • et al.
        Cardiac-resynchronization therapy for mild-to-moderate heart failure.
        N Engl J Med. 2010; 363: 2385-2395
        • Linde C.
        • Abraham W.T.
        • Gold M.R.
        • et al.
        Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.
        J Am Coll Cardiol. 2008; 52: 1834-1843
        • Brignole M.
        • Gammage M.
        • Puggioni E.
        • et al.
        Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation.
        Eur Heart J. 2005; 26: 712-722
        • Brignole M.
        • Botto G.
        • Mont L.
        • et al.
        Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial.
        Eur Heart J. 2011; 32: 2420-2429
        • Doshi R.N.
        • Daoud E.G.
        • Fellows C.
        • et al.
        Left ventricular–based cardiac stimulation post AV nodal ablation evaluation (the PAVE study).
        J Cardiovasc Electrophysiol. 2005; 16: 1160-1165
        • Gasparini M.
        • Auricchio A.
        • Regoli F.
        • et al.
        Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation.
        J Am Coll Cardiol. 2006; 48: 734-743
        • Wilton S.B.
        • Leung A.A.
        • Ghali W.A.
        • et al.
        Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis.
        Heart Rhythm. 2011; 8: 1088-1094
        • Wilkoff B.L.
        • Cook J.R.
        • Epstein A.E.
        • et al.
        Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.
        JAMA. 2002; 288: 3115-3123
        • Adelstein E.
        • Schwartzman D.
        • Gorcsan 3rd, J.
        • Saba S.
        Predicting hyperresponse among pacemaker-dependent nonischemic cardiomyopathy patients upgraded to cardiac resynchronization.
        J Cardiovasc Electrophysiol. 2011; 22: 905-911
        • Vatankulu M.A.
        • Goktekin O.
        • Kaya M.G.
        • et al.
        Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices.
        Am J Cardiol. 2009; 103: 1280-1284
        • Rickard J.
        • Bassiouny M.
        • Cronin E.M.
        • et al.
        Predictors of response to cardiac resynchronization therapy in patients with a non–left bundle branch block morphology.
        Am J Cardiol. 2011; 108: 1576-1580
        • Masci P.G.
        • Marinelli M.
        • Piacenti M.
        • et al.
        Myocardial structural, perfusion, and metabolic correlates of left bundle branch block mechanical derangement in patients with dilated cardiomyopathy: a tagged cardiac magnetic resonance and positron emission tomography study.
        Circ Cardiovasc Imaging. 2010; 3: 482-490
        • Kashani A.
        • Barold S.S.
        Significance of QRS complex duration in patients with heart failure.
        J Am Coll Cardiol. 2005; 46: 2183-2192
        • Doval H.C.
        • Nul D.R.
        • Grancelli H.O.
        • et al.
        Randomised trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA).
        Lancet. 1994; 344: 493-498
        • Bleeker G.B.
        • Schalij M.J.
        • Molhoek S.G.
        • et al.
        Relationship between QRS duration and left ventricular dyssynchrony in patients with end-stage heart failure.
        J Cardiovasc Electrophysiol. 2004; 15: 544-549
        • Blanc J.J.
        • Etienne Y.
        • Gilard M.
        • et al.
        Evaluation of different ventricular pacing sites in patients with severe heart failure: results of an acute hemodynamic study.
        Circulation. 1997; 96: 3273-3277
        • Prinzen F.W.
        • Vernooy K.
        • De Boeck B.W.L.
        • et al.
        Mechano-energetics of the asynchronous and resynchronized heart.
        Heart Fail Rev. 2011; 16: 215-224
        • Ukkonen H.
        • Sundell J.
        • Knuuti J.
        Effects of CRT on myocardial innervation, perfusion and metabolism.
        Europace. 2008; 10: iii114-iii117
        • Cazeau S.
        • Leclercq C.
        • Lavergne T.
        • et al.
        Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay.
        N Engl J Med. 2001; 344: 873-880
        • Stellbrink C.
        • Breithardt O.A.
        • Franke A.
        • et al.
        Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances.
        J Am Coll Cardiol. 2001; 38: 1957-1965
        • Bradley D.J.
        • Bradley E.A.
        • Baughman K.L.
        • et al.
        Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials.
        JAMA. 2003; 289: 730-740
        • Haghjoo M.
        • Bagherzadeh A.
        • Fazelifar A.F.
        • et al.
        Prevalence of mechanical dyssynchrony in heart failure patients with different QRS durations.
        Pacing Clin Electrophysiol. 2007; 30: 616-622
        • Stavrakis S.
        • Lazzara R.
        • Thadani U.
        The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis.
        J Cardiovasc Electrophysiol. 2012; 23: 163-168
        • Sipahi I.
        • Carrigan T.P.
        • Rowland D.Y.
        • et al.
        Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials.
        Arch Intern Med. 2011; 171: 1454-1462
        • Saxon L.A.
        • Ellenbogen K.A.
        Resynchronization therapy for the treatment of heart failure.
        Circulation. 2003; 108: 1044-1048
        • Bilchick K.C.
        • Kamath S.
        • DiMarco J.P.
        • Stukenborg G.J.
        Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients.
        Circulation. 2010; 122: 2022-2030
        • Adelstein E.C.
        • Saba S.
        Usefulness of baseline electrocardiographic QRS complex pattern to predict response to cardiac resynchronization.
        Am J Cardiol. 2009; 103: 238-242
        • Rickard J.
        • Kumbhani D.J.
        • Gorodeski E.Z.
        • et al.
        Cardiac resynchronization therapy in non–left bundle branch block morphologies.
        Pacing Clin Electrophysiol. 2010; 33: 590-595
        • Upadhyay G.A.
        • Choudhry N.K.
        • Auricchio A.
        • et al.
        Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies.
        J Am Coll Cardiol. 2008; 52: 1239-1246
        • Beshai J.F.
        • Grimm R.A.
        • Nagueh S.F.
        • et al.
        Cardiac-resynchronization therapy in heart failure with narrow QRS complexes.
        N Engl J Med. 2007; 357: 2461-2471
        • Ariga R.
        • Tayebjee M.H.
        • Benfield A.
        • et al.
        Greater three-dimensional ventricular lead tip separation is associated with improved outcome after cardiac resynchronization therapy.
        Pacing Clin Electrophysiol. 2010; 33: 1490-1496
        • Singh J.P.
        • Klein H.U.
        • Huang D.T.
        • et al.
        Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial.
        Circulation. 2011; 123: 1159-1166
        • Linde C.
        • Leclercq C.
        • Rex S.
        • et al.
        Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study.
        J Am Coll Cardiol. 2002; 40: 111-118
        • Sweeney M.O.
        • Prinzen F.W.
        A new paradigm for physiologic ventricular pacing.
        J Am Coll Cardiol. 2006; 47: 282-288
        • Sharma A.D.
        • Rizo-Patron C.
        • Hallstrom A.P.
        • et al.
        Percent right ventricular pacing predicts outcomes in the DAVID trial.
        Heart Rhythm. 2005; 2: 830-834
        • Steinberg J.S.
        • Fischer A.
        • Wang P.
        • et al.
        The clinical implications of cumulative right ventricular pacing in the Multicenter Automatic Defibrillator Trial II.
        J Cardiovasc Electrophysiol. 2005; 16: 359-365
        • Lindenfeld J.
        • Feldman A.M.
        • Saxon L.
        • et al.
        Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure.
        Circulation. 2007; 115: 204-212
        • Amin M.S.
        • Fox A.D.
        • Kalahasty G.
        • et al.
        Benefit of primary prevention implantable cardioverter-defibrillators in the setting of chronic kidney disease: a decision model analysis.
        J Cardiovasc Electrophysiol. 2008; 19: 1275-1280
        • Abraham W.T.
        • Young J.B.
        • León A.R.
        • et al.
        Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure.
        Circulation. 2004; 110: 2864-2868
        • Daubert C.
        • Gold M.R.
        • Abraham W.T.
        • et al.
        Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.
        J Am Coll Cardiol. 2009; 54: 1837-1846
        • Singh J.P.
        • Gras D.
        Biventricular pacing: current trends and future strategies.
        Eur Heart J. 2012; 33: 305-313
        • Stevenson W.G.
        • Hernandez A.F.
        • Carson P.E.
        • et al.
        Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee.
        J Card Fail. 2012; 18: 94-106
        • Dickstein K.
        • Vardas P.E.
        • Auricchio A.
        • et al.
        2010 Focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy.
        Eur Heart J. 2010; 31: 2677-2687
        • Dubner S.
        • Auricchio A.
        • Steinberg J.S.
        • et al.
        ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs).
        Europace. 2012; 14: 278-293
        • Crossley G.H.
        • Chen J.
        • Choucair W.
        • et al.
        Clinical benefits of remote versus transtelephonic monitoring of implanted pacemakers.
        J Am Coll Cardiol. 2009; 54: 2012-2019
        • Crossley G.H.
        • Boyle A.
        • Vitense H.
        • et al.
        The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts.
        J Am Coll Cardiol. 2011; 57: 1181-1189
        • Varma N.
        • Epstein A.E.
        • Irimpen A.
        • et al.
        Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial.
        Circulation. 2010; 122: 325-332
        • Mabo P.
        • Victor F.
        • Bazin P.
        • et al.
        A randomized trial of long-term remote monitoring of pacemaker recipients (the COMPAS trial).
        Eur Heart J. 2012; 33: 1105-1111
        • Saxon L.A.
        • Hayes D.L.
        • Gilliam F.R.
        • et al.
        Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study.
        Circulation. 2010; 122: 2359-2367